U.S. Preventive Services Task Force

Screening for Cognitive Impairment in Older Adults: Recommendation Statement

 

Am Fam Physician. 2020 Jun 15;101(12):online.

As published by the USPSTF.

Related Putting Prevention into Practice: Screening for Cognitive Impairment in Older Adults

Summary of Recommendation

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults (Table 1). I statement.

See Table 1 for a more detailed summary of the recommendation for clinicians. See the Practice Considerations section for suggestions for practice regarding the I statement.

 Enlarge     Print

TABLE 1.

Screening for Cognitive Impairment in Older Adults: Clinical Summary of the USPSTF Recommendation

What does the USPSTF recommend?

For asymptomatic, community-dwelling adults ≥ 65 years: I statement The USPSTF found that the evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults. More research is needed.

To whom does this recommendation apply?

Community-dwelling adults ≥ 65 years without recognized signs or symptoms of cognitive impairment It does not apply to persons who are hospitalized or living in institutions such as nursing homes.

What’s new?

This recommendation is consistent with the 2014 USPSTF statement.

How to implement this recommendation?

There is insufficient evidence to recommend for or against screening for cognitive impairment. Clinicians should remain alert to early signs or symptoms of cognitive impairment (e.g., problems with memory or language) and evaluate as appropriate.

Where to read the full recommendation statement?

Visit the USPSTF website (https://www.uspreventiveservicestaskforce.org) to read the full recommendation statement. This includes more details on the rationale of the recommendation, including benefits and harms; supporting evidence; and recommendations of others.


Note: For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, go to https://www.uspreventiveservicestaskforce.org/.

USPSTF = U.S. Preventive Services Task Force.

TABLE 1.

Screening for Cognitive Impairment in Older Adults: Clinical Summary of the USPSTF Recommendation

What does the USPSTF recommend?

For asymptomatic, community-dwelling adults ≥ 65 years: I statement The USPSTF found that the evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults. More research is needed.

To whom does this recommendation apply?

Community-dwelling adults ≥ 65 years without recognized signs or symptoms of cognitive impairment It does not apply to persons who are hospitalized or living in institutions such as nursing homes.

What’s new?

This recommendation is consistent with the 2014 USPSTF statement.

How to implement this recommendation?

There is insufficient evidence to recommend for or against screening for cognitive impairment. Clinicians should remain alert to early signs or symptoms of cognitive impairment (e.g., problems with memory or language) and evaluate as appropriate.

Where to read the full recommendation statement?

Visit the USPSTF website (https://www.uspreventiveservicestaskforce.org) to read the full recommendation statement. This includes more details on the rationale of the recommendation, including benefits and harms; supporting evidence; and recommendations of others.


Note: For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, go to https://www.uspreventiveservicestaskforce.org/.

USPSTF = U.S. Preventive Services Task Force.

Importance

According to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5), dementia (also known as major neurocognitive disorder) is defined by a significant decline in 1 or more cognitive domains that interferes with a person’s independence in daily activities. The 6 cognitive domains identified in the DSM-5 are complex attention, executive function, learning and memory, language, perceptual motor function, and social cognition.1 Dementia affects an estimated 2.4 to 5.5 million persons in the United States, and its prevalence increases with age. Dementia affects an estimated 3.2% of persons aged 65 to 74 years, 9.9% of those aged 75 to 84 years, and 29.3% of those 85 years or older.2

Mild cognitive impairment (MCI) differs from dementia in that the impairment is not severe enough to interfere with independent daily functioning. Some persons with MCI may progress to dementia, whereas some do not. One systematic review found that 32% of persons with MCI develop dementia over 5 years.3 However, studies have also shown that between 10% and 40% of persons with MCI may return to normal cognition over approximately 4 to 5 years.46 The prevalence of MCI is difficult to estimate, in part because of differing diagnostic criteria, leading to a wide range of prevalence estimates (3%–42%) in adults 65 years or older.7,8 In this recommendation statement, cognitive impairment refers to both dementia and MCI.

USPSTF Assessment of Magnitude of Net Benefit

The USPSTF concludes that the evidence is lacking, and the balance of benefits and harms of screening for cognitive impairment cannot be determined (Table 1 and Table 2).

 Enlarge     Print

TABLE 2.

Summary of USPSTF Rationale

RationaleAssessment

Detection

Adequate evidence that some screening tools have relatively high sensitivity and specificity for the detection of dementia When the prevalence of dementia is high (e.g., in persons ≥ 85 years), positive predictive values can be greater than 50%. However, because of lower prevalence, the positive predictive value can be closer to 20% in unselected populations of adults aged 65 to 74 years Sensitivity and specificity of screening tools are generally lower for the detection of MCI than they are for dementia

Benefits of early detection and intervention and treatment

Inadequate direct evidence on the benefits of screening for cognitive impairment Adequate evidence that AChEIs and memantine have a small effect on measures of cognitive function in the short term for patients with mild to moderate dementia, but it is uncertain whether the effects reported in studies are clinically meaningful or sustained over the long term Inadequate evidence on the benefits of other medications or supplements (e.g., statins, antihypertensives, vitamins) and nonpharmacologic interventions targeted to patients Adequate evidence that interventions to support caregivers have a small effect on measures of caregiver burden and depression, but the clinical importance of these effects is uncertain, and the generalizability of these findings to persons with previously unrecognized dementia, detected by screening, is not known Inadequate evidence on the benefits of interventions targeting decision-making or planning by patients, caregivers, or clinicians

Harms of early detection and intervention and treatment

Inadequate direct evidence on the harms of screening for cognitive impairment Inadequate evidence on the harms of nonpharmacologic interventions targeted at the patient, caregiver, or both Adequate evidence that AChEIs are associated with adverse effects, which overall are small but occasionally serious, including syncope or falls

USPSTF assessment

Evidence on screening for cognitive impairment is lacking and the balance of benefits and harms cannot be determined


Note: For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, go to https://www.uspreventiveservicestaskforce.org/.

AChEI = acetylcholinesterase inhibitor; MCI = mild cognitive impairment; USPSTF = U.S. Preventive Services Task Force.

TABLE 2.

Summary of USPSTF Rationale

RationaleAssessment

Detection

Adequate evidence that some screening tools have relatively high sensitivity and specificity for the detection of dementia When the prevalence of dementia is high (e.g., in persons ≥ 85 years), positive predictive values can be greater than 50%. However, because of lower prevalence, the positive predictive value can be closer to 20% in unselected populations of adults aged 65 to 74 years Sensitivity and specificity of screening tools are generally lower for the detection of MCI than they are for dementia

Benefits of early detection and intervention and treatment

Inadequate direct evidence on the benefits of screening for cognitive impairment Adequate evidence that AChEIs and memantine have a small effect on measures of cognitive function in the short term for patients with mild to moderate dementia, but it is uncertain whether the effects reported in studies are clinically meaningful or sustained over the long term Inadequate evidence on the benefits of other medications or supplements (e.g., statins, antihypertensives, vitamins) and nonpharmacologic interventions targeted to patients Adequate evidence that interventions to support caregivers have a small effect on measures of caregiver burden and depression, but the clinical importance of these effects is uncertain, and the generalizability of these findings to persons with previously unrecognized dementia, detected by screening, is not known Inadequate evidence on the benefits of interventions targeting decision-making or planning by patients, caregivers, or clinicians

Harms of early detection and intervention and treatment

Inadequate direct evidence on the harms of screening for cognitive impairment Inadequate evidence on the harms of nonpharmacologic interventions targeted at the patient, caregiver, or both Adequate evidence that AChEIs are associated with adverse effects, which overall are small but occasionally serious, including syncope or falls

USPSTF assessment

Evidence on screening for cognitive impairment is lacking and the balance of benefits and harms cannot be determined


Note: For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, go to https://www.uspreventiveservicestaskforce.org/.

AChEI = acetylcholinesterase inhibitor; MCI = mild cognitive impairment; USPSTF = U.S. Preventive Services Task Force.

Practice Considerations

PATIENT POPULATION UNDER CONSIDERATION

This recommendation applies to community-dwelling adults 65 years or older, without recognized signs or symptoms of cognitive impairment. Early detection and diagnosis of dementia through the assessment of signs and symptoms recognized by the patient, family, or clinician, which may be subtle, are not considered screening and are therefore not the focus of this recommendation.

RISK ASSESSMENT

Increasing age is the strongest known risk factor for cognitive impairment.9 The ε4 allele of the apolipoprotein E (apoE) gene is a reported risk factor for Alzheimer disease in white and Asian populations.10 Other risk factors include cardiovascular risk factors (e.g., diabetes, hypertension, or hypercholesterolemia), depression, physical frailty, low education level, and low social support level.1013 Several dietary and lifestyle factors have been reported as associated with decreased risk of cognitive impairment. These include adequate folic acid intake, low saturated fat intake, higher longer-chain omega-3 fatty acid intake, high fruit and vegetable intake, the Mediterranean diet, moderate alcohol intake (1 to 6 drinks per week vs. abstention), higher educational attainment, cognitive engagement, social engagement, and higher physical activity levels.10,11,14,15

SCREENING TESTS

Many different brief screening tests for cognitive impairment are available. Screening tests generally include asking patients to perform a series of tasks that assess 1 or more domains of cognitive function. These tests are not intended to diagnose MCI or dementia. A positive screening test result should lead to additional testing that can include blood tests, radiology examinations, and a medical and neuropsychologic evaluation to confirm the diagnosis of dementia and determine its subtype.

The most well-studied screening instrument is the Mini-Mental State Examination (MMSE). Other screening instruments include the clock drawing test (CDT), Memory Impairment Screen (MIS)/MIS by Telephone (MIS-T), Mental Status Questionnaire (MSQ), Mini-Cog verbal fluency, 8-Item Informant Interview (AD8), Functional Activities Questionnaire (FAQ), 7-Minute Screen (7MS), Abbreviated Mental Test (AMT), Montreal Cognitive Assessment (MoCA), St. Louis University Mental Status Examination (SLUMS), Telephone Instrument for Cognitive Status (TICS), and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). For more information on all screening instruments reviewed by the USPSTF, see the full evidence report.16,17

TREATMENT AND INTERVENTIONS

Treatment of cognitive impairment may focus on one or more signs and symptoms, including cognition, quality of life, mood, and behavioral impairments.

Several pharmacologic and nonpharmacologic interventions aim to slow, prevent, or reverse cognitive impairment; stabilize or improve functional performance; improve caregiver burden and depression; or improve patient, caregiver, and clinician decision-making. Pharmacologic treatments approved by the U.S. Food and Drug Administration for Alzheimer disease include acetylcholinesterase inhibitors (AChEIs) and memantine. Nonpharmacologic inter ventions include cognitive training, cognitive rehabilitation, cognitive stimulation inter ventions, exercise, peer support, psychoeducation, and care management.

SUGGESTIONS FOR PRACTICE REGARDING THE I STATEMENT

Potential Preventable Burden. Dementia affects an estimated 2.4 to 5.5 million persons in the United States, and its prevalence increases with age. Dementia affects an estimated 9.9% of persons aged 75 to 84 years and 29.3% of those 85 years or older.2 Subjective memory issues are common in adults, with studies showing that approximately 50%18 to 75%19 of adults have at least minor concerns about their memory.

Although there is insufficient evidence to recommend for or against screening for cognitive impairment, there may be important reasons to identify cognitive impairment early. Burdens of cognitive impairment include direct effects on the patient (e.g., loss of function and relationships, financial misjudgments, nonadherence with recommended therapies), direct effects on caregivers (e.g., burden, depression), and effects on society (e.g., costs of care). Early detection of cognitive impairment can allow for identification and treatment of reversible causes, may help clinicians anticipate problems patients may have in understanding and adhering to medical treatment plans, and may also be useful by providing a basis for advance planning on the part of patients and families. Clinicians should remain alert to early signs or symptoms of cognitive impairment (e.g., problems with memory or language) and evaluate the individual as appropriate. However, none of the potential benefits of screening have been clearly demonstrated in clinical trials.

Potential Harms. Evidence about the harms of screening is limited. One potential harm is labeling a person with an illness that is typically progressive and for which treatment appears to have limited effectiveness. Some studies have shown higher stress, greater depression, and lower quality of life in persons aware of a diagnosis of cognitive impairment,20 whereas others have found no such association.21,22 Evidence about the effects of false-positive results is limited. AChEIs are associated with harms, some of which are serious, including central nervous system disturbances, bradycardia, and falls. Evidence about the harms of nonpharmacologic interventions is limited, but these harms are assumed to be small.

Current Practice. Most commonly, evaluation for or diagnosis of cognitive impairment occurs as a result of patient- or caregiver-reported concerns or symptoms or clinician’s suspicion. As many as 29% to 76% of patients with dementia are unrecognized in the primary care setting.2325 In 2011, Medicare added detection of cognitive impairment to its annual wellness visit. The Centers for Medicare & Medicaid Services recommends assessing a patient’s cognitive function by direct observation; considering information and concerns reported by the patient, family members, friends, caregivers, and others; and, if deemed appropriate, using a brief validated, structured cognitive assessment tool.26

Additional Tools and Resources

The National Institute on Aging has useful information on the definition, detection, and management of cognitive impairment for patients and clinicians, including links to some screening instruments, on its website.27

Other Related USPSTF Recommendations

The USPSTF has recommendations related to several risk factors for cognitive impairment, including pharmacotherapy and counseling for tobacco cessation28; screening and counseling to reduce unhealthy alcohol use29; counseling to promote healthful diet and physical activity30,31; statins to reduce cardiovascular disease risk32; and screening for hypertension,33 abnormal blood glucose levels,34 and depression.35

This recommendation statement was first published in JAMA. 2020;323(8):764–785.

The USPSTF recommendations are independent of the U.S. government. They do not represent the views of the Agency for Healthcare Research and Quality, the U.S. Department of Health and Human Services, or the U.S. Public Health Service.

The “Update of Previous USPSTF Recommendation,” “Supporting Evidence,” “Research Needs and Gaps,” and “Recommendations of Others” sections of this recommendation statement are available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cognitive-impairment-in-older-adults-screening#fullrecommendationstart.

References

show all references

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013....

2. Langa KM, Larson EB, Crimmins EM, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177(1):51–58.

3. Ward A, Tardiff S, Dye C, et al. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320–332.

4. Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008;63(4):494–506.

5. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59(10):1594–1599.

6. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5):342–351.

7. Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment—a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand. 2002;106(6):403–414.

8. Ward A, Arrighi HM, Michels S, et al. Mild cognitive impairment. Alzheimers Dement. 2012;8(1):14–21.

9. Holsinger T, Deveau J, Boustani M, et al. Does this patient have dementia? JAMA. 2007;297(21):2391–2404.

10. Plassman BL, Williams JW Jr, Burke JR, et al. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med. 2010;153(3):182–193.

11. Ritchie K, Carrière I, Ritchie CW, et al. Designing prevention programmes to reduce incidence of dementia. BMJ. 2010;341:c3885.

12. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–2734.

13. Boyle PA, Buchman AS, Wilson RS, et al. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J Am Geriatr Soc. 2010;58(2):248–255.

14. Cooper C, Sommerlad A, Lyketsos CG, et al. Modifiable predictors of dementia in mild cognitive impairment. Am J Psychiatry. 2015;172(4):323–334.

15. Mukamal KJ, Kuller LH, Fitzpatrick AL, et al. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA. 2003;289(11):1405–1413.

16. Patnode CD, Perdue LA, Rossom RC, et al. Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force. Evidence synthesis no. 189. AHRQ publication no. 19-05257-EF-1. Agency for Healthcare Research and Quality; 2019.

17. Patnode CD, Perdue LA, Rossom RC, et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020;323(8):764–785.

18. Luck T, Roehr S, Rodriguez FS, et al. Memory-related subjective cognitive symptoms in the adult population: prevalence and associated factors—results of the LIFE-Adult-Study. BMC Psychol. 2018;6(1):23.

19. Ginó S, Mendes T, Maroco J, et al. Memory complaints are frequent but qualitatively different in young and elderly healthy people. Gerontology. 2010;56(3):272–277.

20. Stites SD, Karlawish J, Harkins K, et al. Awareness of mild cognitive impairment and mild Alzheimer’s disease dementia diagnoses associated with lower self-ratings of quality of life in older adults. J Gerontol B Psychol Sci Soc Sci. 2017;72(6):974–985.

21. Mormont E, Jamart J, Jacques D. Symptoms of depression and anxiety after the disclosure of the diagnosis of Alzheimer disease. J Geriatr Psychiatry Neurol. 2014;27(4):231–236.

22. Mate KE, Pond CD, Magin PJ, et al. Diagnosis and disclosure of a memory problem is associated with quality of life in community based older Australians with dementia. Int Psychogeriatr. 2012;24(12):1962–1971.

23. Chodosh J, Petitti DB, Elliott M, et al. Physician recognition of cognitive impairment. J Am Geriatr Soc. 2004;52(7):1051–1059.

24. Olafsdóttir M, Skoog I, Marcusson J. Detection of dementia in primary care: the Linköping study. Dement Geriatr Cogn Disord. 2000;11(4):223–229.

25. Valcour VG, Masaki KH, Curb JD, et al. The detection of dementia in the primary care setting. Arch Intern Med. 2000;160(19):2964–2968.

26. Centers for Medicare & Medicaid Services (CMS). Annual wellness visit. August 2018. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/AWV_Chart_ICN905706.pdf

27. U.S. Department of Health and Human Services. National Institute on Aging. Accessed April 10, 2020. https://www.nia.nih.gov/

28. U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(8):622–634.

29. US Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(18):1899–1909.

30. U.S. Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(8):587–593.

31. US Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without cardiovascular risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2017;318(2):167–174.

32. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement [published correction appears in JAMA. 2020;323(7):669–670]. JAMA. 2016;316(19):1997–2007.

33. U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778–786.

34. US Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(11):861–868.

35. US Preventive Services Task Force. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(4):380–387.

This summary is one in a series excerpted from the Recommendation Statements released by the USPSTF. These statements address preventive health services for use in primary care clinical settings, including screening tests, counseling, and preventive medications.

The complete version of this statement, including supporting scientific evidence, evidence tables, grading system, members of the USPSTF at the time this recommendation was finalized, and references, is available on the USPSTF website at https://www.uspreventiveservicestaskforce.org/.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

A collection of USPSTF recommendation statements published in AFP is available at https://www.aafp.org/afp/uspstf.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP

More in Pubmed

MOST RECENT ISSUE


Jul 1, 2020

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article